In-hospital resource utilization, worsening heart failure, and factors associated with length of hospital stay in patients with hospitalized heart failure: A Japanese database cohort study

J Cardiol. 2020 Oct;76(4):342-349. doi: 10.1016/j.jjcc.2020.05.010. Epub 2020 Jul 4.

Abstract

Background: Our objective was to characterize cases of hospitalized heart failure (HHF) focusing on in-hospital resource utilization (particularly furosemide doses) and worsening heart failure (WHF), and identify which factors are associated with the length of stay (LOS).

Methods: Cases of HHF (≥20 years), excluding those undergoing surgical procedures and in-hospital deaths, were retrieved from the Japanese Diagnosis Procedure Combination database (April 2012 to March 2016). WHF was defined using eight components, including up-titration of intravenous drugs and non-pharmacological management.

Results: The mean age of 78,953 cases of HHF was 79 years and 51% were male. The median LOS was 17 days. The maximum daily dose and cumulative dose of furosemide (mean ± standard deviation) were 43.3 ± 56.0 mg and 215.6 ± 450.6 mg, respectively, for intravenous furosemide, and 44.0 ± 37.3 mg and 523.3 ± 675.4 mg, respectively, for oral furosemide. The incidence of WHF was 36.1% during hospitalization and 19.3% from 6th hospital day to discharge. The mean number of WHF components was 1.4 ± 0.7 during hospitalization and 1.3 ± 0.6 from 6th hospital day. Regression analyses showed that the number of WHF components from 6th hospital day, pneumonia, and hyponatremia were strongly associated with longer LOS.

Conclusions: These findings in patients with HHF could be vital to focus future efforts to improve the therapeutic strategies for heart failure.

Keywords: Factors for length of stay; Furosemide dose; Heart failure hospitalization; Worsening heart failure.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aged, 80 and over
  • Cohort Studies
  • Databases, Factual
  • Disease Progression
  • Female
  • Furosemide / therapeutic use
  • Heart Failure* / drug therapy
  • Hospitalization
  • Humans
  • Hyponatremia
  • Japan
  • Male
  • Pneumonia
  • Sodium Potassium Chloride Symporter Inhibitors / therapeutic use

Substances

  • Sodium Potassium Chloride Symporter Inhibitors
  • Furosemide